This month’s issue of Ophthalmology Times Europe saw the publication of a review article, “The pathophysiology and pathomorphology of corneal ectasia” authored by Prof. Hafezi, Medical Director of the ELZA Institute, and Dr. Omid Kermani, Managing Director at Augenklinik am Neumarkt in Cologne.
ELZA’s Medical Director, Prof. Farhad Hafezi has returned from Antalya, Turkey, where he gave a lecture entitled “Frontiers in Cross-Linking in Keratoconus” to the delegates of the
The advantages of performing corneal cross-linking (CXL) at the slit lamp are well established. It brings CXL out of the operating theater, to anywhere where
The ELZA team of surgeons and researchers were all in attendance, and today saw Prof. Hafezi give the attending delegates a lecture on “How to treat thin corneas”, where he examined the history of performing corneal cross-linking (CXL) for the treatment of corneal ectasias like keratoconus. He then brought delegates up-to-date on the research that has been performed over the years to improve how thin corneas are cross-linked. Finally, Prof. Hafezi demonstrated the results of the latest thin cornea cross-linking protocol, sub400, developed by ELAZA, which simplifies the process, and can let surgeons, for the first time, cross-link corneas that are as thin as 200 µm.
The ELZA team of surgeons and researchers were all in attendance, and today saw Prof. Hafezi give the attending delegates a lecture on “How to treat thin corneas”, where he examined the history of performing corneal cross-linking (CXL) for the treatment of corneal ectasias like keratoconus. He then brought delegates up-to-date on the research that has been performed over the years to improve how thin corneas are cross-linked. Finally, Prof. Hafezi demonstrated the results of the latest thin cornea cross-linking protocol, sub400, developed by ELAZA, which simplifies the process, and can let surgeons, for the first time, cross-link corneas that are as thin as 200 µm.
The ELZA team of surgeons and researchers were all in attendance, and today saw Prof. Hafezi give the attending delegates a lecture on “How to treat thin corneas”, where he examined the history of performing corneal cross-linking (CXL) for the treatment of corneal ectasias like keratoconus. He then brought delegates up-to-date on the research that has been performed over the years to improve how thin corneas are cross-linked. Finally, Prof. Hafezi demonstrated the results of the latest thin cornea cross-linking protocol, sub400, developed by ELAZA, which simplifies the process, and can let surgeons, for the first time, cross-link corneas that are as thin as 200 µm.
This week saw the publication of ELZA’s better pain management protocol in the Journal of Clinical Medicine, and represents a significant advance in the way pain
Newsflash: CXL reimbursed in Switzerland
Exactly 20 years after the clinical introduction of cross-linking and after more than 2,000 scientific publications on the subject, corneal cross-linking (CXL) for the treatment of progressive keratoconus has now been included in the Swiss healthcare reimbursement system (the “krankenkasse”).
